Download Poster (1.6 MB)
- Pancreatic ductal adenocarcinoma (PDA) remains a deadly disease with a 5-year survival of 8% for all stages combined (Siegel RL et al.). Currently, it’s the third leading cause of cancer-related deaths in the United States and by 2020 it is projected to become the second leading cause (Rahib L, et al).
- The poor prognosis in PDA is in part due to the limited therapies that are currently available.
- This highlights the importance of high-throughput technologies for gene expression analyses and drug screens.
- A recently developed NanoString Technologies nCounter® analysis system, an example of high-throughput technology, utilizes a color-coded barcode to directly measure multiple mRNA transcripts simultaneously.
- Our ability to study RNA expression has classically been limited by low detection rate (microarrays) or high cost (RNA-Seq).
- We utilized the nCounter® analysis system to measure changes in cancer-associated gene expression in PDA cell lines caused by different drug treatment.
- We then validated these results using traditional assays to evaluate the sensitivity of the nCounter® analysis system.
Poster presented at: Metro Philadelphia Chapter of the American College of Surgeons in Philadelphia PA, United States.
Evaluating the Sensitivity of the NanoStrong nCounter® Analysis System to Determine Gene Expression Changes Associated with Chemotherapy Treatment, poster, Department of Surgery, Thomas Jefferson University
Dukleska, MD, Katerina; Schultz, BS, Christopher W.; Zarei, PhD, Mahsa; McKeown, MD, David; Yeo, MD, Charles J.; Brody, PhD, Jonathan; and Winter, MD, Jordan M., "Evaluating the Sensitivity of the NanoStrong nCounter® Analysis System to Determine Gene Expression Changes Associated with Chemotherapy Treatment" (2000). Department of Surgery Posters. 9.